Zealand Pharma(DE:22Z)
€33.20+1.19 (+7.51%)
DE:22Z
Zealand Pharma stock forecast
€33.20
At close:+1.19 (+7.51%)
Zealand Pharma (22Z) Stock Forecast & Price Target
19 Followers
22Z Analyst Ratings
Moderate Buy
1Buy1Hold0Sell
Based on 2 analysts giving stock ratings to Zealand Pharma in the past 3 months
22Z Stock 12 Month Forecast
Average Price Target
EUR 51.18▲(54.15% Upside)Based on 2 Wall Street analysts offering 12 month price targets for Zealand Pharma in the last 3 months. The average price target is EUR 51.18 with a high forecast of EUR 58.20 and a low forecast of EUR 44.15. The average price target represents a 54.15% change from the last price of EUR 33.20.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 58.20
AverageEUR 51.18
LowEUR 44.15
Highest Price TargetHighestEUR 58.20Average Price TargetEUR 51.18Lowest Price TargetLowestEUR 44.15
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Yihan Li | Barclays | EUR 56.87→EUR 44.15 | hold | 32.99%Upside | Downgraded | 09/08/26 | ||
| Sophia Graeff Buhl-Nielsen | J.P. Morgan | EUR 61.55→EUR 58.20 | buy | 75.31%Upside | Reiterated | 08/25/26 | ||
| Benjamin Jackson CFA | Jefferies | EUR 67.57→EUR 42.82 | hold | 28.96%Upside | Downgraded | 07/13/26 | ||
| Kerry Holford | Berenberg Bank | EUR 110.39→EUR 40.14 | hold | 20.90%Upside | Downgraded | 06/16/26 | ||
| Emmanuel Papadakis | Deutsche Bank | EUR 36.80→EUR 40.14 | hold | 20.90%Upside | Reiterated | 06/04/26 | ||
| Xian Deng | UBS | EUR 97.67 | buy | 194.20%Upside | Reiterated | 05/08/26 | ||
| Thomas Bowers | SEB Enskilda | EUR 50.84→EUR 63.56 | buy | 91.43%Upside | Upgraded | 04/29/26 | ||
| Martin Brenoe | Nordea Markets | ― | hold | ― | Downgraded | 03/06/26 | ||
| Prakhar Agrawal | Cantor Fitzgerald | ― | hold | ― | Downgraded | 03/06/26 | ||
| Andy Hsieh | William Blair | ― | hold | ― | Downgraded | 03/06/26 | ||
| Kirsty Ross Stewart | Exane BNP Paribas | EUR 36.80 | hold | 10.83%Upside | Downgraded | 03/06/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Yihan LiBarclays | HoldDowngradedEUR 56.87→EUR 44.15 | 09/08/26 | 32.99%Upside | ||
| Sophia Graeff Buhl-NielsenJ.P. Morgan | BuyReiteratedEUR 61.55→EUR 58.20 | 08/25/26 | 75.31%Upside | ||
| Benjamin Jackson CFAJefferies | HoldDowngradedEUR 67.57→EUR 42.82 | 07/13/26 | 28.96%Upside | ||
| Kerry HolfordBerenberg Bank | HoldDowngradedEUR 110.39→EUR 40.14 | 06/16/26 | 20.90%Upside | ||
| Emmanuel PapadakisDeutsche Bank | HoldReiteratedEUR 36.80→EUR 40.14 | 06/04/26 | 20.90%Upside | ||
| Xian DengUBS | BuyReiteratedEUR 97.67 | 05/08/26 | 194.20%Upside | ||
| Thomas BowersSEB Enskilda | BuyUpgradedEUR 50.84→EUR 63.56 | 04/29/26 | 91.43%Upside | ||
| Martin BrenoeNordea Markets | HoldDowngraded | 03/06/26 | ― | ||
| Prakhar AgrawalCantor Fitzgerald | HoldDowngraded | 03/06/26 | ― | ||
| Andy HsiehWilliam Blair | HoldDowngraded | 03/06/26 | ― | ||
| Kirsty Ross StewartExane BNP Paribas | HoldDowngradedEUR 36.80 | 03/06/26 | 10.83%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Zealand Pharma
3 Months
Success Rate1/2 ratings generated profit
50%
Average Return
+7.05%
Copying Thomas Bowers's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.05% per trade.
1 Year
Success Rate1/2 ratings generated profit
50%
Average Return
-6.00%
Copying Thomas Bowers's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -6.00% per trade.
2 Years
Success Rate1/2 ratings generated profit
50%
Average Return
-6.00%
Copying Thomas Bowers's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -6.00% per trade.
22Z Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 0 |
| Hold | 3 | 3 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 5 | 4 | 3 | 2 | 1 |
In the current month, 22Z has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 22Z average Analyst price target in the past 3 months is 51.18.
22Z Financial Forecast
HighEUR -1.23
ConsensusEUR -1.39
LowEUR -1.58
22Z Earnings Forecast
Next quarter’s earnings estimate for 22Z is -EUR 1.39 with a range of -EUR 1.58 to -EUR 1.23. The previous quarter’s EPS was EUR 7.40. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 2.81M
ConsensusEUR 1.18M
LowEUR 0.00
22Z Sales Forecast
Next quarter’s sales forecast for 22Z is EUR 1.18M with a range of EUR 0 to EUR 2.81M. The previous quarter’s sales results were EUR 600.79M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
22Z Stock Forecast FAQ
What is DE:22Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Zealand Pharma’s 12-month average price target is €51.18.
What is DE:22Z’s upside potential, based on the analysts’ average price target?
Zealand Pharma has 54.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Zealand Pharma a Buy, Sell or Hold?
Zealand Pharma has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is Zealand Pharma’s share price target?
The average share price target for Zealand Pharma is €51.18. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €58.20, and the lowest forecast is €44.15. The average share price target represents a 54.15% increase from the current price of €33.2.
What do analysts say about Zealand Pharma?
Zealand Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Zealand Pharma?
To buy shares of DE:22Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
